Prices for new US drugs doubled in 4 years as focus on rare disease grows
By Deena Beasley (Reuters) -U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...
Read moreDetailsBy Deena Beasley (Reuters) -U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...
Read moreDetails
